KALA BIO, Inc.
KALA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479419
No open-market purchases or sales by KALA BIO, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.21M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding KALA BIO, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 25 | 29 | +4 |
| Shares | 525.9K | 616.8K | +90.9K (+17.3%) |
| Value | $3.68M | $4.88M | +$1.20M (+32.7%) |
New holders (4)
Institutions that held KALA BIO, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Oconnor LLC | 72,554 | $568.8K | 0.02% |
| Citadel Advisors LLC | 13,468 | $105.6K | 0.00% |
| The PNC Financial Services Group, Inc. | 20 | $159 | 0.00% |
| Old Point Trust & Financial Services N A | 20 | $159 | 0.00% |
Sold out (0)
Institutions that held KALA BIO, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
None.